Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL

Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy

Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC

Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL

Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age